As competition in health ingredients diversifies in terms of sources and applications, Greenyn Biotech focuses on independent research and development, continuously expanding its international specialty ingredient portfolio through clinical scientific validation capabilities. A strategic memorandum of understanding (MOU) was signed with Korean raw materials company RAWGA, marking the beginning of the exclusive Taiwan collaboration for "Korean VC-H1®Roselle Extract"; At the same time, as the exclusive agent in Taiwan, the company introduce Norway's Seagarden's "Norwegian Cod Testicle Extract (including PDRN)" in Taiwan, echoing the international trend of plant-based peptides and oral beauty ingredient applications. Dr. Hsu Bang-Kui, General Manager of Greenyn Biotech, stated that by combining plant-based sources, scientific evidence, and sustainable raw material concepts, VC-H1® will develop next-generation beauty and health products for Taiwanese brands, offering differentiated options from traditional animal collagen.

Greenyn, the Grand Prize Winner of the ASPA Award 2025, exemplifies the outstanding innovation and impact that companies within Asia’s science park ecosystems can achieve. These developments highlight the growing importance of international collaboration in advancing innovation, expanding market opportunities, and creating sustainable value across the health ingredient and biotechnology sectors.

Read Full Article